Navigation Links
Receptos Files Registration Statement for Proposed Initial Public Offering
Date:4/4/2013

SAN DIEGO, April 4, 2013 /PRNewswire/ -- Receptos, Inc., a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.  All shares of the common stock to be sold in the offering will be offered by Receptos.  The number of shares to be offered and the price range for the offering have not yet been determined.

Credit Suisse Securities (USA) LLC, Leerink Swann LLC and BMO Capital Markets are acting as joint book-running managers for the offering.  Wedbush PacGrow Life Sciences is acting as a co-manager.  The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, Telephone: (800) 221-1037, Email: newyork.prospectus@credit-suisse.com; from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, Telephone: (800) 808-7525, Email: syndicate@leerink.com; or from BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor  (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated Orphan Disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).

Media and Investor Contact: 
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com

 

 

 

 


'/>"/>
SOURCE Receptos, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
2. Receptos to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
3. Graham Cooper Appointed Chief Financial Officer of Receptos
4. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
5. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
6. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
7. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
8. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
9. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
10. Sunpeaks Ventures Files Defamation Lawsuit
11. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):